Characterisation of Fundamental Decision Making in People Suffering From a Characterised Depressive Episode
MINDDE
1 other identifier
observational
80
1 country
1
Brief Summary
The investigators will include patients suffering from Major Depressive Disorder (MDD), in episode. The patients will undertake neuropsychological tasks evaluating executive function and clinical assessment related to depressive symptoms, anxiety, transdiagnostic symptoms and psychological skills.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 25, 2022
CompletedFirst Posted
Study publicly available on registry
December 16, 2022
CompletedStudy Start
First participant enrolled
February 9, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 25, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 25, 2024
CompletedDecember 9, 2024
December 1, 2024
1.2 years
November 25, 2022
December 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
MADRS score
The severity of the depression will be assessed using the MADRS score. Montgomery-Asberg Depression Scale (MADRS) The scale has 10 items rated from 0 to 6. 0 to 6 points: the patient is considered healthy. 7 to 19 points: the patient is considered to be in mild depression. 20 to 34 points: the patient is considered to be in moderate depression. \> 34 points: the patient is considered to be in severe depression.
baseline
Simple reaction time (SRT) obtained at the MindPulse test
The "simple reaction time" (SRT) is the reaction time to the first test (the subject releases the mouse click as quickly as possible when an image appears) , it contains the time needed to perceive and analyse the image, to formulate the response and to execute the motor response.
Baseline
Go/NoGo score obtained at the MindPulse test
reaction time with a categorisation where the subject must react or not react (Go/NoGo) according to the categorical target, in this case a light or dark colour (white coloured image or grey coloured image).
Baseline
Executive speed (ES) obtained at the MindPulse test
The ES Score corresponds to the Executive Speed, i.e. the average time of categorisation of the subject.
Baseline
Reaction to difficulty obtained at the MindPulse test
It corresponds to the adaptation of the subject to the level of difficulty. The shift of the circle above the blue rectangle indicates a higher than expected slowing down in reaction to the difficulty of the instruction, while a shift below the blue rectangle indicates that the participant is not slowing down enough in response to the difficulty and is at risk of making mistakes.
Baseline
Secondary Outcomes (7)
Level of anxiety
Baseline
clinical characterisation
Baseline
clinical characterisation
Baseline
insomnia severity
Baseline
Stroop test
Baseline
- +2 more secondary outcomes
Interventions
In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
Eligibility Criteria
people suffering from a characterised depressive episode
You may qualify if:
- Age between 18 and 65 years.
- Diagnosis of a depressive episode according to DSM-5 criteria, confirmed by the Mini International Neuropsychiatric Interview (MINI 7.0 according to DSM-5).
- No evidence of bipolar disorder or schizophrenia, confirmed by the MINI.
- No dementing neurological disease.
- No guardianship or trusteeship
You may not qualify if:
- Opposition to data processing
- Depressive episode in the context of a known bipolar disorder or schizophrenic illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clinique psychiatrique universitaire
Tours, 37044, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wissam EL HAGE
CHU Tours
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 25, 2022
First Posted
December 16, 2022
Study Start
February 9, 2023
Primary Completion
April 25, 2024
Study Completion
April 25, 2024
Last Updated
December 9, 2024
Record last verified: 2024-12